Multi-omics integration reveals m6A epitranscriptomic regulators as central drivers of a prognostic immune-metabolic axis in glioblastoma.
Glioblastoma (GBM) is the most aggressive primary brain malignancy, with a median survival of approximately 15 months despite current standard-of-care treatment. N6-methyladenosine (m6A) RNA modification regulates gene expression, but its relationship with miRNA-mediated regulation, metabolism, and prognosis in GBM rem...